Single-chain antibody and its derivatives directed against vascular endothelial growth factor: Application for antiangiogenic gene therapy

Gene Therapy

Volumn 10, Issue 21, 2003, Pages 1850-1859

  Afanasieva, T A ^a,c   Wittmer, M ^a   Vitaliti, A ^a   Ajmo, M ^a   Neri, D ^b   Klemenz, R ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b ETH ZURICH   (Switzerland)

^c DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Angiogenesis; Gene therapy; Single chain antibody; Tumor; VEGF

Indexed keywords

ADENOVIRUS VECTOR; ANGIOGENESIS INHIBITOR; HYBRID PROTEIN; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; VASCULOTROPIN; VASCULOTROPIN ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DRUG EFFICACY; GENE EXPRESSION; GENE IDENTIFICATION; HALF LIFE TIME; IN VIVO STUDY; MOUSE; MULTIPLE DRUG DOSE; NONHUMAN; PHAGE DISPLAY; PRIORITY JOURNAL; PROTEIN TARGETING; SINGLE DRUG DOSE; TUMOR VASCULARIZATION; VIRAL GENE THERAPY; VIRUS RECOMBINANT;

ADENOVIRIDAE; ANIMALS; CELL LINE; COS CELLS; ENDOTHELIAL GROWTH FACTORS; GENE THERAPY; GENETIC ENGINEERING; GENETIC VECTORS; HUMANS; IMMUNOGLOBULIN FRAGMENTS; IMMUNOGLOBULIN VARIABLE REGION; INJECTIONS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LYMPHOKINES; MICE; MICE, NUDE; NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

ADENOVIRIDAE; ANIMALIA;

EID: 0141613928     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3302085     Document Type: Article

References (37)

1. Folkman J. Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Engl J Med 1995; 333: 1757-1763.
2. Ferrara N et al. The vascular endothelial growth factor family of polypeptides. J Cell Biochem 1991; 47: 211-218.
3. Ferrara N. VEGF: an update on biological and therapeutic aspects. Curr Opin Biotechnol 2000; 11: 617-624.
4. Shibuya M et al. Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family Oncogene 1990; 5: 519-524.
5. de Vries C et al. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 1992; 255: 989-991.
6. Hasan J, Jayson GC. VEGF antagonists. Expert Opin Biol Ther 2001; 1: 703-718.
7. Winter G, Griffiths AD, Hawkins RE, Hoogenboom HR. Making antibodies by phage display technology. Annu Rev Immunol 1994; 12: 433-455.
8. Huston JS et al. Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. Proc Natl Acad Sci USA 1988; 85: 5879-5883.
9. Yokota T et al. Microautoradiographic analysis of the normal organ distribution of radioiodinated single-chain Fv and other immunoglobulin forms. Cancer Res 1993; 53: 3776-3783.
10. Vitaliti A et al. Inhibition of tumor angiogenesis by a single-chain antibody directed against vascular endothelial growth factor. Cancer Res 2000; 60: 4311-4314.
11. Feldman AL, Libutti SK. Progress in antiangiogenic gene therapy of cancer. Cancer 2000; 89: 1181-1194.
12. Chen QR, Zhang L, Gasper W, Mixson AJ. Targeting tumor angiogenesis with gene therapy. Mol Genet Metab 2001; 74: 120-127.
13. Reff ME, Heard C. A review of modifications to recombinant antibodies: attempt to increase efficacy in oncology applications. Crit Rev Oncol Hematol 2001; 40: 25-35.
14. Borsi L et al. Selective targeting of tumoral vasculature: comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin. Int J Cancer 2002; 102: 75-85.
15. Hardy S et al. Construction of adenovirus vectors through Crelox recombination. J Virol 1997; 71: 1842-1849.
16. Vajkoczy P et al. Microtumor growth initiates angiogenic sprouting with simultaneous expression of VEGF, VEGF receptor-2, and angiopoietin-2. J Clin Invest 2002; 109: 777-785.
17. Gabrilovich DI et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 1996; 2: 1096-1103.
18. Gabrilovich DI et al. Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function. Clin Cancer Res 1999; 5: 2963-2970.
19. Wong AK et al. Excessive tumor-elaborated VEGF and its neutralization define a lethal paraneoplastic syndrome. Proc Natl Acad Sci USA 2001; 98: 7481-7486.
20. Colcher D et al. In vivo tumor targeting of a recombinant single-chain antigen-binding protein. J Natl Cancer Inst 1990; 82: 1191-1197.
21. Ghetie V, Ward ES. FcRn: the MHC class I-related receptor that is more than an IgG transporter. Immunol Today 1997; 18: 592-598.
22. Ober RJ, Radu CG, Ghetie V, Ward ES. Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies. Int Immunol 2001; 13: 1551-1559.
23. Neri D et al. Targeting by affinity-matured recombinant antibody fragments of an angiogenesis associated fibronectin isoform. Nat Biotechnol 1997; 15: 1271-1275.
24. Pini A et al. Hierarchical affinity maturation of a phage library derived antibody for the selective removal of cytomegalovirus from plasma. J Immunol Methods 1997; 206: 171-182.
25. Lam PY, Breakefield XO. Hybrid vector designs to control the delivery, fate and expression of transgenes. J Gene Med 2000; 2: 395-408.
26. Morral N et al. Administration of helper-dependent adenoviral vectors and sequential delivery of different vector serotype for long-term liver-directed gene transfer in baboons. Proc Natl Acad Sci USA 1999; 96: 12816-12821.
27. Reynolds PN et al. Combined transductional and transcriptional targeting improves the specificity of transgene expression in vivo. Nat Biotechnol 2001; 19: 838-842.
28. Trepel M, Arap W, Pasqualini R. In vivo phage display and vascular heterogeneity: implications for targeted medicine. Curr Opin Chem Biol 2002; 6: 399-404.
29. Gupta VK et al. Vascular endothelial growth factor enhances endothelial cell survival and tumor radioresistance. Cancer J 2002; 8: 47-54.
30. Browder T et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000; 60: 1878-1886.
31. Klement G et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 2000; 105: R15-R24.
32. Arafat WO et al. Effective single chain antibody (scFv) concentrations in vivo via adenoviral vector mediated expression of secretory scFv. Gene Therapy 2002; 9: 256-262.
33. Sanz L et al. Single-chain antibody-based gene therapy: inhibition of tumor growth by in situ production of phage-derived human antibody fragments blocking functionally active sites of cell-associated matrices. Gene Therapy 2002; 9: 1049-1053.
34. Fallaux FJ et al. Characterization of 911: a new helper cell line for the titration and propagation of early region 1-deleted adenoviral vectors. Hum Gene Ther 1996; 7: 215-222.
35. Klemenz R, Hoffmann S, Werenskiold AK. Serum- and oncoprotein-mediated induction of a gene with sequence similarity to the gene encoding carcinoembryonic antigen. Proc Natl Acad Sci USA 1989; 86: 5708-5712.
36. Jonsson U et al. Real-time biospecific interaction analysis using surface plasmon resonance and a sensor chip technology. Biotechniques 1991; 11: 620-627.
37. Halin C et al. Tumor targeting properties of antibody-VEGF fusion proteins. Int. J. Cancer 2002; 102: 109-116.